title: Outcome of ST-elevation myocardial infarction versus non-ST-elevation acute coronary syndrome treated with titanium-nitride-oxide-coated versus everolimus-eluting stents: insights from the BASE-ACS trial.
abstract: OBJECTIVE
  The BASE-ACS trial demonstrated an outcome of titanium-nitride-oxide-coated bioactive stents (BAS) that was statistically non-inferior to that of everolimus-eluting stents (EES) at 12-month follow-up, in patients presenting with acute coronary syndrome (ACS) who underwent early percutaneous coronary intervention (PCI). We explored a post-hoc analysis of the 12-month outcome of the BASE-ACS trial in the subgroup of patients with ST-elevation myocardial infarction (STEMI) versus non-ST-elevation ACS (non-STEACS).
  
  
  METHODS
  A total of 827 patients with ACS (321 STEMI) were randomly assigned to receive either BAS or EES. The primary endpoint was a composite of cardiac death, non-fatal myocardial infarction (MI) and ischemia-driven target lesion revascularization (TLR) at 12-month follow-up.
  
  
  RESULTS
  The 12-month cumulative incidence of the primary endpoint was similar between the two subgroups (9% versus 9.5%, in STEMI versus non-STEACS patients respectively, P=0.90). The 12-month rate of cardiac death was significantly higher in the STEMI subgroup as compared with the non-STEACS subgroup (2.8 versus 0.6%, respectively, P=0.01). However, the rates of non-fatal MI, ischemia-driven TLR, definite stent thrombosis, and non-cardiac death were all statistically matched between the two subgroups (P>0.05 for all).
  
  
  CONCLUSIONS
  In the current post-hoc analysis of the BASE-ACS trial based on the infarction type, the 12-month outcome of patients who underwent early PCI for ACS was slightly worse in the setting of STEMI as compared with non-STEACS, as reflected by a significantly higher rate of cardiac death.
authors.affiliation: Department of Internal Medicine, University of Oulu, Oulu, Finland.
authors.forename: H
authors.initials: H
authors.lastname: Romppanen
authors.forename: W
authors.initials: W
authors.lastname: Nammas
authors.forename: K
authors.initials: K
authors.lastname: Kervinen
authors.forename: J
authors.initials: J
authors.lastname: Mikkelsson
authors.forename: M
authors.initials: M
authors.lastname: Pietilä
authors.forename: J
authors.initials: J
authors.lastname: Lalmand
authors.forename: F
authors.initials: F
authors.lastname: Rivero-Crespo
authors.forename: M
authors.initials: M
authors.lastname: Pentikäinen
authors.forename: P
authors.initials: P
authors.lastname: Tedjokusumo
authors.forename: P P
authors.initials: PP
authors.lastname: Karjalainen
mesh_terms: D054058:Acute Coronary Syndrome / Q000188:drug therapy / Q000601:surgery*; D000368:Aged; D000925:Anticoagulants / Q000627:therapeutic use; D020099:Coated Materials, Biocompatible; D003131:Combined Modality Therapy; D023903:Coronary Restenosis / Q000453:epidemiology; D018572:Disease-Free Survival; D054855:Drug-Eluting Stents; D000068338:Everolimus; D005260:Female; D005500:Follow-Up Studies; D006331:Heart Diseases / Q000401:mortality; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D015337:Multicenter Studies as Topic / Q000706:statistics & numerical data*; D009203:Myocardial Infarction / Q000188:drug therapy / Q000601:surgery*; D017202:Myocardial Ischemia / Q000453:epidemiology / Q000601:surgery; D062645:Percutaneous Coronary Intervention; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D011183:Postoperative Complications / Q000401:mortality; D016032:Randomized Controlled Trials as Topic; D020123:Sirolimus / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D014025:Titanium; D016896:Treatment Outcome
chemical_list: D000925:Anticoagulants; D020099:Coated Materials, Biocompatible; D010975:Platelet Aggregation Inhibitors; C434243:titanium-nitride-oxide; D000068338:Everolimus; D014025:Titanium; D020123:Sirolimus